Top 6 Research Reports For June 29, 2016
Zacks Investment Research | Jun 29, 2016 02:35AM ET
Wednesday, June 29, 2016
In today's long line-up of research reports, we want to highlight Amgen (NASDAQ:AMGN) (AMGN), Kraft Heinz (KHC), and UPS (UPS)
Amgen shares have been weak lately given the overall tough environment for the space, but this Zack Rank # 2 (Buy) biotech major is well-positioned for growth with several blockbuster drugs in its portfolio. (F .
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. He also provides weekly commentary to click here
Today's Must Read/h6
Featured Reports/h6
Gilead has received a boost with the FDA approving the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection.
AbbVie terminated its partnership with Infinity for the development and commercialization of duvelisib (cancer) and returned global rights to the candidate.
The Zacks analyst stresses that Whirlpool has reassured investors following Brexit by reiterating its earnings guidance for 2016.
Termination of the merger will impact shareholders since they will miss a cash payment and lose the chance to own a stake in a stronger combined entity, according to the covering analyst.
The deal, on closing, will create the world's largest manufacturer of food and beverage cans.
While Brexit has increased volatility in Expedia shares, the Zacks analyst thinks its strong order growth and contribution from acquisitions will be the major growth drivers.
The covering analyst feels revenue growth will remain muted given rising macro concerns after the Brexit vote while Moody's ratings outlook revisions will have an adverse impact on its financials.
Gilead has received a boost with the FDA approving the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection.
AbbVie terminated its partnership with Infinity for the development and commercialization of duvelisib (cancer) and returned global rights to the candidate.
The Zacks analyst stresses that Whirlpool has reassured investors following Brexit by reiterating its earnings guidance for 2016.
Termination of the merger will impact shareholders since they will miss a cash payment and lose the chance to own a stake in a stronger combined entity, according to the covering analyst.
The deal, on closing, will create the world's largest manufacturer of food and beverage cans.
While Brexit has increased volatility in Expedia shares, the Zacks analyst thinks its strong order growth and contribution from acquisitions will be the major growth drivers.
The covering analyst feels revenue growth will remain muted given rising macro concerns after the Brexit vote while Moody's ratings outlook revisions will have an adverse impact on its financials.
New Upgrades/h6
The Zacks analyst believes Shire has been making timely aquisitions to diversify its portfolio and the recent Baxalta acquisition strengthens its hematology, oncology and immunology franchises.n
Archer Daniels is strategically undertaking steps to manage its business portfolio, which is expected to help in realizing value, according to the covering analyst. n
The Zacks analyst stresses that ADP's higher revenue per client and lower cost of operations gives it an edge amid volatile macro-economic backdrop and a strengthening U.S dollar.
The Zacks analyst believes Shire has been making timely aquisitions to diversify its portfolio and the recent Baxalta acquisition strengthens its hematology, oncology and immunology franchises.n
Archer Daniels is strategically undertaking steps to manage its business portfolio, which is expected to help in realizing value, according to the covering analyst. n
The Zacks analyst stresses that ADP's higher revenue per client and lower cost of operations gives it an edge amid volatile macro-economic backdrop and a strengthening U.S dollar.
New Downgrades/h6
The Zacks analyst thinks United Technologies is susceptible to operating risks following the referendum given its considerable presence in the Britain.
The covering analyst believes currency headwinds, possible softer fountain food-service volumes, higher health and welfare insurance costs will hurt profits in the second quarter.n
Barclays' outlook was cut to negative by Moody's in the wake of Brexit concerns while fundamental weakness persist, according to the covering analyst.
The Zacks analyst thinks United Technologies is susceptible to operating risks following the referendum given its considerable presence in the Britain.
The covering analyst believes currency headwinds, possible softer fountain food-service volumes, higher health and welfare insurance costs will hurt profits in the second quarter.n
Barclays' outlook was cut to negative by Moody's in the wake of Brexit concerns while fundamental weakness persist, according to the covering analyst.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.